Research programme: cell therapy - HemoGenyx

Drug Profile

Research programme: cell therapy - HemoGenyx

Alternative Names: Hu PHEC expanded; Hu PHEC liver; Hu PHEC Umbilical

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemogenyx
  • Developer Cornell University; Hemogenyx
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Aplastic anaemia; Haematological disorders

Most Recent Events

  • 30 Oct 2017 Hemogenyx has patents pending for Hu PHEC Liver (Hemogenyx website, October 2017) before October 2017
  • 30 Oct 2017 Hemogenyx has patents pending for Hu PHEC Umbilical (Hemogenyx website, October 2017) before October 2017
  • 30 Oct 2017 Preclinical trials in Aplastic anaemia in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top